Evidence omicron risk is higher for blood cancer patients

[Bartlet]

after two vaccine doses, neutralising antibodies against omicron was detectable in 19% patients against delta was detetable in 39% against original SARS-CoV-2 in 89% patients (p<0.0001).

After third vaccine dose, against omicron was 56% against delta 71% and original 86%.

CLL patients may have lower rates than general blood cancer patients.

[lankisterguy Volunteer]

Hi Bartlet,

-

Thanks for posting that data.

-

Can you please provide a link to the source or give a specific reference for the publication or author?

-

Len

[Bartlet in reply to lankisterguy]

Sorry. It’s here thelancet.com/journals/lanc...

[bennevisplace in reply to Bartlet]

Thanks for posting this.

For blood cancer patients the most telling findings seem to be

"None of ten patients who received anti-CD20 and one of five patients who received BTKi had detectable nAbT against omicron following three vaccine doses. The presence of progressive disease versus complete response following the most recent anticancer treatment was also significantly associated with undetectable NAbT against omicron (OR 0·08 [95% CI 0·01–0·46], p=0·027). Blood cancer subtype, vaccine type administered as first and second dose, and age were not significantly associated with detectable NAbT against omicron".

[OmBewok in reply to bennevisplace]

Thanks very much for highlighting this. I found it very helpful. Regards. OmBewok